Lewis K, Maio M, Demidov L, et al. BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma. ESMO 2017, abstract LBA7_PR.
Nivolumab plus ipilimumab versus lenvatinib of sorafenib bij inoperabel hepatocellulair carcinoom
jul 2025 | Hepatologie, Immuuntherapie, Maag-darm-leveroncologie